Compare GSK plc (GSK) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs KB Financial Group, Inc. — how do they compare? GSK plc trades at $52.85 (market cap $101.34B), while KB Financial Group, Inc. trades at $120.81 (market cap $41.90B). The key difference: GSK plc is far larger — about 2.4× KB Financial Group, Inc.'s market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | KB | |
|---|---|---|
Market Cap | $101.34B | $41.90B |
Sector | Health | Financials |
52-Week High | $61.18 | $123.25 |
52-Week Low | $36.20 | $77.50 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | 2.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
KB Financial Group (KB) trades at $121.85, up 0.94% with strong technical momentum as moving averages signal bullish conditions. The company demonstrates robust fundamentals with revenue growth from $21.23T in 2025 to $21.67T projected for 2026, net income margin expanding to 27.82%, and consistent earnings beats in recent quarters. Recent news highlights aggressive non-banking diversification and potential dividend increases.
The outlook remains positive with valuation metrics appearing reasonable (P/E 11.69, P/B 1.12) and analyst consensus leaning bullish despite mixed ratings. Key risks include execution of diversification strategy and market volatility, while institutional sentiment is supported by ROE expansion potential and strong cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
